Marshall Wace, LLP Opti Nose, Inc. Transaction History

Marshall Wace, LLP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$1.17 - $1.94 $359,907 - $596,769	307,613 New	307,613 $449,000
Q2 2023 Aug 14, 2023	BUY	$1.11 - $2.05 $87,613 - $161,808	78,931 Added 264.59%	108,762 $133,000
Q4 2022 Feb 14, 2023	BUY	$1.68 - $3.7 $50,116 - $110,374	29,831 New	29,831 $55,000
Q1 2021 May 17, 2021	SELL	$3.47 - $4.75 $117,365 - $160,659	-33,823 Closed	0 $0
Q3 2020 Nov 16, 2020	SELL	$3.69 - $7.09 $64,003 - $122,976	-17,345 Reduced 33.9%	33,823 $132,000
Q2 2020 Aug 13, 2020	SELL	$3.58 - $7.44 $222,908 - $463,251	-62,265 Reduced 54.89%	51,168 $380,000
Q1 2020 May 15, 2020	BUY	$3.49 - $9.2 $382,448 - $1.01 Million	109,584 Added 2847.08%	113,433 $509,000
Q4 2019 Feb 14, 2020	BUY	$6.27 - $11.41 $24,133 - $43,917	3,849 New	3,849 $35,000

88.3M

Ticker OPTN
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 83,277,504
Market Cap $31.6M
Description
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically-acting cort...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.